EUVIMEDEUVIMED entdecken
Scoping Review

A Scoping Review of Clinical Trials on the Expanding Role of Beta‑Blockers in Dermatology

Yasamin Dehghan iD, Armin Gorjian, Zahra Rezaee, Mohammadreza Keshtkar, Mohammad Mahdi Parvizi, Elham Hassannia, Negin Fazelzadeh Haghighi

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026

DOI: 10.1111/ddg.70283 ↗

Kurz gefasst

Scoping Review in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2026. Verfasst von Yasamin Dehghan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Skin Diseases. Die Arbeit nennt 91 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Beta‐blockers have been proven to be safe and effective treatments for various medical conditions, but their full potential in dermatology remains to be fully understood. We conducted a comprehensive review of clinical trials published between January 2000 and August 2025. 41 studies were included, exploring the use of beta‐blockers for any dermatological conditions, involving over 4,000 people worldwide. Our findings show strong evidence that beta‐blockers are the first‐line treatment for infantile hemangiomas. Additionally, they reduce mortality in patients with burns, accelerate wound healing in chronic venous and diabetic ulcers, and improve skin graft donor sites. Emerging data suggest benefits in rosacea, pyogenic granulomas, post‑procedural erythema, and as an adjunct to immune checkpoint inhibitors in melanoma, alongside a favorable safety profile in clinical trials. However, beta‑blockers can exacerbate inflammatory dermatoses, may interfere with the management of anaphylaxis, and exert complex effects on cutaneous immunity. Overall, beta‑blockers are evolving into versatile dermatologic tools whose expanding indications must be balanced against their immunologic and cardiovascular risks, and further high‑quality trials are needed to standardize their use in these emerging applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-AntagonistsSkin DiseasesHumansClinical Trials as TopicWound HealingDermatology

Stichwörter der Autor:innen

Beta‐blockerInfantile HemangiomaPropranololTimololWound Healing

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Internal Medicine, School of medicine, Kerman University of medical sciences, Kerman, Iran.

ORCID-Profile: Yasamin Dehghan

Zitieren

APA

Dehghan, Y., Gorjian, A., Rezaee, Z., Keshtkar, M., Parvizi, M. M., Hassannia, E., & Haghighi, N. F. (2026). A Scoping Review of Clinical Trials on the Expanding Role of Beta‑Blockers in Dermatology. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.70283

Vancouver

Dehghan Y, Gorjian A, Rezaee Z, Keshtkar M, Parvizi MM, Hassannia E, et al. A Scoping Review of Clinical Trials on the Expanding Role of Beta‑Blockers in Dermatology. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.70283

BibTeX
@article{Dehghan2026,
  author = {Dehghan, Yasamin and Gorjian, Armin and Rezaee, Zahra and Keshtkar, Mohammadreza and Parvizi, Mohammad Mahdi and Hassannia, Elham and Haghighi, Negin Fazelzadeh},
  title = {A Scoping Review of Clinical Trials on the Expanding Role of Beta‑Blockers in Dermatology},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2026},
  doi = {10.1111/ddg.70283}
}
Kostenlos starten →